Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

January 31, 2017

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Ticagrelor

Ticagrelor 90mg twice daily for 5 weeks

DRUG

Prasugrel

Prasugrel 10mg once daily for 5 weeks

Trial Locations (1)

Korea University Anam Hospital, Seoul